We investigated the association between the interleukin 6 (IL-6)-174-genotype and unfavorable outcomes in preterm infants since it has been reported that the IL-6-174GG-genotype is associated with increased susceptibility to sepsis, and the IL-6-174CC-genotype is more common in preterm infants with severe intraventricular hemorrhage (IVH). We studied 1206 preterm infants with a birth weight below 1500 g. In contrast to previously published data, the frequency of IVH grade IV, periventricular leukomalacia, ventricular-peritoneal-shunting or death was not different between infants with different IL-6-genotypes: IL-6-174GG (n ¼ 430) 8%, IL-6-174GC (n ¼ 605) 9% and IL-6-174CC (n ¼ 167) 12% (P ¼ 0.2 for IL-6-174CC vs GG þ GC). Furthermore, we were not able to confirm previously reported association between sepsis and the IL-6-174GG-genotype. Blood-culture-proven sepsis occurred in 19% of IL-6-174GG-carriers (n ¼ 157), 26% of IL-6-174GC-carriers (n ¼ 193) and 27% of infants carrying the IL-6-174CC-genotype (n ¼ 67). We were not able to confirm previously reported associations between sepsis, cerebral injury and the IL-6-174-genotype in VLBW-infants.
Genetic association studies are powerful tools to identify populations who are at risk for certain diseases. Recently, two independent groups reported an association between the G-Allele of the interleukin-6-174-promotor (IL-6-174) variant and an increased risk of blood-cultureproven sepsis in preterm infants. 1, 2 Furthermore, one of these groups subsequently reported a high prevalence of serious hemorrhagic brain injuries and periventricular leukomalacia (PVL) in preterm infants carrying the homozygous IL-6-174-C-genotype. 3 Functional data concerning the effects of the IL-6-174-polymorphism are conflicting. [4] [5] [6] Since a genetic marker predictive for sepsis and brain damage in preterm infants would be a valuable tool to select patients for preventive therapies, we studied the effect of the IL6-174-genotype in a large prospectively enrolled cohort of very low birth weight (VLBW)-infants to confirm the results of Harding et al.
1,2 and our initial report concerning the association between IL6-174 and sepsis. Furthermore, we analyzed the effect of the IL6-174-genotype on intraventricular hemorrhage (IVH) and PVL.
Parents of VLBW-infants who were born between 24 þ 0 and 36 þ 6 weeks of gestational age with a birth weight less than 1500 g were asked to participate in our study. Preterm infants, who were born with a gestational age of 23 þ 6 weeks and below were not included in our study, since mortality rate in this group is very high. Infants with lethal malformations (e.g. trisomy 13 and trisomy 18) were also excluded. Data quality was ensured by on site monitoring every 6 months.
Between September 2003 and November 2004 536 VLBW-infants at nine participating centers were eligible for our study and completed follow-up until discharge or death. Of these infants 421 (78.5%) were included. Reasons for not participating the trial were recorded and included lack of enquiring the parents for trial participation (n ¼ 68), rapid death of the infant (n ¼ 29), no consent (n ¼ 10) and other reasons (n ¼ 8). Since the participating centers recorded the main outcome criteria for all VLBW-infants eligible for the study, we were able to estimate if patients not included differ from included infants with regard to main outcome measures. However, there were no differences with regard to the frequency of blood-culture-proven sepsis (included infants 23.5 vs 20.9% in infants not included), IVH (18.9 vs 19.1%) and PVL (3.8 vs 2.6%). Genotyping of the IL-6-174-polymorphism was successful in 99% (417 of 421) of all VLBW-infants who participated in our trial.
We furthermore identified 785 additional VLBWinfants in our database, whose clinical data comply with the inclusion criteria of our current trial. IL-6-174-genotyping data associated with sepsis was already reported of 356 of these infants, 2 but IL-6-genotype association to IVH and PVL has not been reported yet. Clinical data of both groups are given in Table 1 . Allelefrequencies were 0.608 for the IL-6-174G-allele and 0.392 for the IL-6-174C-allele, respectively. Genotype distribution was in Hardy-Weinberg-equilibrium for the whole group and all subgroups.
In our current study, 97 of 417 infants sustained bloodculture-proven sepsis. Only 15 of 97 infants developed their first sepsis during the first 3 days of life (early onset), whereas the majority of septic events were late onset. Coagulase-negative Staphylococcus was the single most common pathogen, accounting for 43% (n ¼ 42) of all infections. Other pathogens detected were Staphylococcus aureus (n ¼ 13), enterococcus (n ¼ 8), group B Streptococci (n ¼ 6), Escherichia coli (n ¼ 6), Klebsiella sp. (n ¼ 5), Candida albicans (n ¼ 4) and other (n ¼ 13). In all, 21 infants sustained a second and four of these infants a third episode of sepsis. Again, coagulase negative Staphylococcus was the most prevalent pathogen (n ¼ 8).
We analyzed the frequency of sepsis, Gram-positivesepsis and repeated episodes of sepsis in infants with different IL-6-174-genotypes (Table 2 ). Since vancomycin is the usual treatment for infants with suspected Grampositive-sepsis, we furthermore analyzed the frequency of vancomycin treatment ( Table 2 ). Mechanical ventilation and intravenous central lines are well known risk factors for blood-stream infections, and prophylactic treatment with vancomycin or teicoplanin is associated with a reduced prevalence of sepsis. We analyzed subgroups of infants who were ventilated (n ¼ 193), had a central line during their stay in the hospital (n ¼ 140) or did not receive chemoprophylaxis (n ¼ 349). Table 2 gives genotype frequencies of the IL-6-174-polymorphism for the whole group and the prevalence for sepsis and Gram-positive sepsis in various subgroups.
The frequency of IVH and PVL was comparable between infants enrolled in our current trial and infants of our previous trials (Table 1) . We therefore analyzed the association of the IL-6-genotype and outcome with regard to IVH and PVL together for both groups. Rates of IVH, PVL and ventricular-peritoneal-shunt in infants with different IL-6-174-genotypes are given in Table 3 . No genotype-phenotype associations with regard to IVH, PVL, VP-shunt or death were observed. This was also true, if data analysis was restricted to the infants of our current trial (data not shown).
IL-6 is an important mediator of the early host response to bacterial infection. Therefore, polymorphic variations of the IL-6-gene are reasonable candidates for altered susceptibility to sepsis and sepsis related outcomes. Many investigators have analyzed the effect of the IL-6-174-genotype on plasma IL-6-concentrations in Sepsis was defined as clinical signs of sepsis confirmed by a positive blood culture at any time during the stay in the hospital. The prevalence of blood culture proven sepsis in previous trials was lower since 55% of these infants were included by a single center, which used prophylactic treatment of all VLBW-infants with teicoplanin. ). Only one group studied newborn infants and reported higher IL-6 levels in infants carrying the IL-6-174-GC or CC-genotype compared to the IL-6-174-GGgenotype. 4 Recently, two groups reported IL-6-174-allele specific human in vivo data after exposure to IL-6-stimulating agents. Endler et al. 5 studied the IL-6-levels after a single bolus injection of 2 ng/kg lipopolysaccaride. IL-6-plasma level increased to a mean value of 427 ng/l but no differences with regard to the IL-6-174-genotype were observed. Bennermo 7 studied the IL-6-response to Salmonella typhi vaccine in adults homozygous for the IL-6-17GG or CC genotype. They reported higher IL-6-levels in carriers of the G-allele 6-10 h after exposure to the vaccination. However, the upper quartile of IL-6-plasma-levels in their study participants did not exceed 10 ng/l -values which are not comparable to those seen in patients with sepsis.
The association of the IL-6-174-genotype with sepsis in preterm infants has been reported recently by three independent groups. Treszel et al. 8 studied 105 VLBW-infants: 33 infants with blood-culture proven sepsis, 35 infants with laboratory and clinical signs of sepsis and 35 control infants. They did not observe any differences with regard to the IL-6-174-genotype between these groups of patients. Harding et al. 1 studied 157 infants born p32 weeks of gestational age. They reported a higher incidence of Intraventricular hemorrhage grade I was defined as blood within the germinal matrix regions, grade II as blood within the ventricular system without distension and not exceeding 50% of the ventricular volume, grade III as blood within the ventricular system exceeding 50% of the ventricular volume or ventricular distention and grade IV as blood within the ventricular system and parenchymal involvement with subsequent parenchymal destruction. Periventricular leukomalacia was defined as one or more echodense lesions which eventually cavitate to become a porencephalic cyst. *P-values are given for IL-6-GG-or GC-genotype, vs IL-6-CC-genotype, Fisher's exact test. Figure 1 Summary of odds ratios and 95% confidence-intervals for infants with and without blood-culture-proven sepsis according to IL-6-174-genotype (GG vs GC or CC) in previously published trials and the current report. The total odds ratio and confidence-interval was determined by Mantel-Haenszel estimates.
Interleukin-6-174-genotype W Göpel et al the IL-6-174GG-genotype in infants who developed septicemia (n ¼ 51). The frequency of the GG-genotype was 0.47 compared to 0.28 in 106 infants without sepsis (P ¼ 0.021). Finally, Ahrens 2 reported a group of 356 VLBW-infants including 50 infants who developed blood-culture-proven sepsis. Again, the IL-6-174-GGgenotype was more frequent in infants with sepsis compared to infants without infection (48 vs 32%, P ¼ 0.039).
We were not able to confirm an association between the IL-6-174-genotype and sepsis. In contrast to previously published data, blood-culture-proven sepsis and Gram-positive-sepsis was less frequent in VLBWinfants carrying the IL-6-174GG-genotype (Table 2, Figure 1 ). If all published trials and our current report are analyzed together, no differences between preterm infants carrying the IL-6-174GG-or the IL-6-174GC/CC-genotype could be observed (OR 1.1, 95%CI 0.8-1.5; determined by Mantel-Haenszel estimates, Figure 1 ).
With regard to the reported association between IVH, PVL and the IL-6-174CC-genotype, we were also not able to confirm previously reported results. Since the total number of infants in our study is considerably higher than the reported number of infants in the initial study by Harding et al. 3 (n ¼ 1202 vs 148), we are convinced that the IL-6-174CC-genotype is not associated with a higher rate of large IVH or PVL. However, we could not rule out the possibility that the IL-6-174CC-genotype is associated with a higher rate of disability in surviving infants, since this was not an endpoint of our study.
How could one explain the apparent differences between our current report and published data of our own and other groups? The most probable explanation is an incidental association of sepsis and IL-6-genotype in previous trials. Another possible explanation are haplotype but not genotype associated outcomes. Recently, it was suggested that IL-6-haplotypes, which could be determined by three polymorphisms at position À172, 1753 and 2954 of the IL-6-gene, are better predictors of mortality in critical ill adults than the IL-6-174 genotype alone. 9 However, only 228 patients participated in this study and the results have not been confirmed so far.
Although we are convinced that susceptibility to sepsis and other diseases of VLBW-infants is influenced by genetic factors, our current results indicate, that several obstacles must be removed until valid and reproducible gene-disease associations are defined. One of the most important steps on this way is the prospective development of large-scale cohorts of preterm infants with well-defined phenotypes and according DNA-samples.
Abbreviations IL-6, interleukin 6; IVH, intraventricular hemorrhage; PVL, periventricular leukomalcia; VLBW, very low birth weight.
